Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07324239
Starting soon Not applicable

TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

NCT07324239 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-01-02
Last updated
2026-01-07

Condition(s) studied

Prostatitis

Investigational drug(s) / intervention(s)

TECAR therapySham TECAR therapy

TECAR therapy: WINBACK 3SE (France) will be used for TECAR therapy in this study. To facilitate optimal distribution of endogenous heat therapy and effective contact between the active electrodes, both capacitive and resistive, and the surface of the skin, a layer of high-conductivity cream will be applied to the treatment region. The plate, an inactive electrode, which has a specific size (21cm\*15cm), will be placed on the gluteal region. The capacitive electrode was employed for a duration of seven and a half minutes, at an intensity of 30-40%, whereas the resistance electrode will be utilized for an equivalent period over the perineum at the same intensity.

Sham TECAR therapy: The procedure is similar to the active treatment of TECAR, but with the critical difference being that the output intensity of the TECAR device will be set to zero during the session.

Study summary

Evaluate the effect of TECAR therapy on pain, voiding, erectile function, sleep quality and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome.

Eligibility

Sex
MALE
Min age
30 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * Presence of chronic prostatitis/chronic pelvic pain symptoms for more than 6 months. * Ages will be ranged from 30 to 50 years old. Exclusion Criteria: 1. Urinary and seminal infections. 2. Recent parenteral steroid administration. 3. Prior prostate or pelvic surgery. 4. Lower urinary tract disorders such as bladder stones. 5. Implanted electronic devices as pacemakers. 6. Sensory loss over the perineum.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tanta University Hospital Tanta Egypt

More Middle East University trials in Egypt

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07324239 on ClinicalTrials.gov ↗ ← All trials in Egypt